Buscar
Pharvaris NV
PHVSAñadir a la lista de seguimiento
33.950USD
-0.630-1.82%
Cierre 07/01, 16:00（ET）Cotizaciones retrasadas 15 min
2.22BCap. mercado
PérdidaP/E TTM
Más Datos de Pharvaris NV Compañía
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Información de Pharvaris NV
Símbolo de cotizaciónPHVS
Nombre de la empresaPharvaris NV
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoModig (Berndt B.A.E)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
DirecciónEmmy Noetherweg 2
CiudadLEIDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal2333 BK
Teléfono31712036410
Sitio Webhttps://pharvaris.com/
Símbolo de cotizaciónPHVS
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoModig (Berndt B.A.E)
Ejecutivos de Pharvaris NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
47.61K
-5.61%
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Pharvaris NV?
Los cinco principales accionistas de Pharvaris NV son: Mr. Berndt Modig, CPA
¿Cuántas instituciones poseen acciones de Pharvaris NV (PHVS)?
A fecha de 2026Q1, 165 instituciones poseen acciones de Pharvaris NV, con un valor de mercado combinado de aproximadamente 59.26M, lo que representa el 90.60% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -451327.00.